Boston Scientific Co. (NYSE:BSX – Get Rating) EVP Wendy Carruthers sold 7,500 shares of the stock in a transaction dated Thursday, April 14th. The stock was sold at an average price of $44.47, for a total transaction of $333,525.00. Following the sale, the executive vice president now directly owns 147,413 shares in the company, valued at $6,555,456.11. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Boston Scientific stock opened at $44.25 on Friday. The company has a market cap of $63.13 billion, a P/E ratio of 64.13, a PEG ratio of 2.45 and a beta of 0.83. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.10 and a current ratio of 1.48. Boston Scientific Co. has a one year low of $37.96 and a one year high of $46.28. The firm has a fifty day moving average of $43.64 and a two-hundred day moving average of $42.83.
Boston Scientific (NYSE:BSX – Get Rating) last announced its quarterly earnings data on Wednesday, February 2nd. The medical equipment provider reported $0.45 EPS for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.01. Boston Scientific had a net margin of 8.63% and a return on equity of 14.43%. The company had revenue of $3.13 billion during the quarter, compared to the consensus estimate of $3.11 billion. During the same quarter in the prior year, the firm earned $0.23 EPS. Boston Scientific’s quarterly revenue was up 15.5% on a year-over-year basis. As a group, equities analysts predict that Boston Scientific Co. will post 1.76 earnings per share for the current year.
Several research firms have recently issued reports on BSX. Truist Financial assumed coverage on shares of Boston Scientific in a research note on Wednesday. They set a “buy” rating and a $52.00 target price on the stock. SVB Leerink cut their price objective on shares of Boston Scientific from $48.00 to $45.00 and set a “market perform” rating for the company in a report on Thursday, February 3rd. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Thursday, March 24th. Morgan Stanley cut their price target on shares of Boston Scientific from $53.00 to $51.00 and set an “overweight” rating for the company in a report on Thursday, February 3rd. Finally, TheStreet downgraded shares of Boston Scientific from a “b” rating to a “c+” rating in a report on Tuesday, March 8th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $49.12.
About Boston Scientific (Get Rating)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
- Get a free copy of the StockNews.com research report on Boston Scientific (BSX)
- Array Technologies Stock Giving Another Ground Floor Entry
- UiPath Stock is Nearing Rock Bottom Down Here
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.